Hillary A Vanderven1,2, Kathleen Wragg1, Fernanda Ana-Sosa-Batiz1, Anne B Kristensen1, Sinthujan Jegaskanda1, Adam K Wheatley1, Deborah Wentworth3, Bruce D Wines4, P Mark Hogarth4, Steve Rockman1,5, Stephen J Kent1,6,7. 1. Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Victoria, Australia. 2. Biomedicine, College of Public Health, Medical and Veterinary Sciences, James Cook University, Douglas, Queensland, Australia. 3. Biostatistics Division, University of Minnesota, Minneapolis. 4. Burnet Institute, Melbourne. 5. Seqirus Ltd, Parkville. 6. Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Health, Central Clinical School, Monash University. 7. Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, University of Melbourne, Parkville, Victoria, Australia.
Abstract
Background: New treatments for severe influenza are needed. Passive transfer of influenza-specific hyperimmune pooled immunoglobulin (Flu-IVIG) boosts neutralizing antibody responses to past strains in influenza-infected subjects. The effect of Flu-IVIG on antibodies with Fc-mediated functions, which may target diverse influenza strains, is unclear. Methods: We studied the capacity of Flu-IVIG, relative to standard IVIG, to bind to Fcγ receptors and mediate antibody-dependent cellular cytotoxicity in vitro. The effect of Flu-IVIG infusion, compared to placebo infusion, was examined in serial plasma samples from 24 subjects with confirmed influenza infection in the INSIGHT FLU005 pilot study. Results: Flu-IVIG contains higher concentrations of Fc-functional antibodies than IVIG against a diverse range of influenza hemagglutinins. Following infusion of Flu-IVIG into influenza-infected subjects, a transient increase in Fc-functional antibodies was present for 1-3 days against infecting and noninfecting strains of influenza. Conclusions: Flu-IVIG contains antibodies with Fc-mediated functions against influenza virus, and passive transfer of Flu-IVIG increases anti-influenza Fc-functional antibodies in the plasma of influenza-infected subjects. Enhancement of Fc-functional antibodies to a diverse range of influenza strains suggests that Flu-IVIG infusion could prove useful in the context of novel influenza virus infections, when there may be minimal or no neutralizing antibodies in the Flu-IVIG preparation.
Background: New treatments for severe influenza are needed. Passive transfer of influenza-specific hyperimmune pooled immunoglobulin (Flu-IVIG) boosts neutralizing antibody responses to past strains in influenza-infected subjects. The effect of Flu-IVIG on antibodies with Fc-mediated functions, which may target diverse influenza strains, is unclear. Methods: We studied the capacity of Flu-IVIG, relative to standard IVIG, to bind to Fcγ receptors and mediate antibody-dependent cellular cytotoxicity in vitro. The effect of Flu-IVIG infusion, compared to placebo infusion, was examined in serial plasma samples from 24 subjects with confirmed influenza infection in the INSIGHT FLU005 pilot study. Results: Flu-IVIG contains higher concentrations of Fc-functional antibodies than IVIG against a diverse range of influenza hemagglutinins. Following infusion of Flu-IVIG into influenza-infected subjects, a transient increase in Fc-functional antibodies was present for 1-3 days against infecting and noninfecting strains of influenza. Conclusions: Flu-IVIG contains antibodies with Fc-mediated functions against influenza virus, and passive transfer of Flu-IVIG increases anti-influenza Fc-functional antibodies in the plasma of influenza-infected subjects. Enhancement of Fc-functional antibodies to a diverse range of influenza strains suggests that Flu-IVIG infusion could prove useful in the context of novel influenza virus infections, when there may be minimal or no neutralizing antibodies in the Flu-IVIG preparation.
Authors: Sinthujan Jegaskanda; Catherine Luke; Heather D Hickman; Mark Y Sangster; Wendy F Wieland-Alter; Jacqueline M McBride; Jon W Yewdell; Peter F Wright; John Treanor; Carrie M Rosenberger; Kanta Subbarao Journal: J Infect Dis Date: 2016-06-28 Impact factor: 5.226
Authors: Anne B Kristensen; William N Lay; Fernanda Ana-Sosa-Batiz; Hillary A Vanderven; Vijaya Madhavi; Karen L Laurie; Louise Carolan; Bruce D Wines; Mark Hogarth; Adam K Wheatley; Stephen J Kent Journal: J Virol Date: 2016-05-27 Impact factor: 5.103
Authors: Sinthujan Jegaskanda; Mary Dawn T Co; John Cruz; Kanta Subbarao; Francis A Ennis; Masanori Terajima Journal: J Infect Dis Date: 2017-03-01 Impact factor: 5.226
Authors: Sinthujan Jegaskanda; Emma R Job; Marit Kramski; Karen Laurie; Gamze Isitman; Robert de Rose; Wendy R Winnall; Ivan Stratov; Andrew G Brooks; Patrick C Reading; Stephen J Kent Journal: J Immunol Date: 2013-01-14 Impact factor: 5.422
Authors: Sinthujan Jegaskanda; Karen L Laurie; Thakshila H Amarasena; Wendy R Winnall; Marit Kramski; Robert De Rose; Ian G Barr; Andrew G Brooks; Patrick C Reading; Stephen J Kent Journal: J Infect Dis Date: 2013-06-28 Impact factor: 5.226
Authors: Hillary A Vanderven; Lu Liu; Fernanda Ana-Sosa-Batiz; Thi Ho Nguyen; Yanmin Wan; Bruce Wines; P Mark Hogarth; Danielle Tilmanis; Arnold Reynaldi; Matthew S Parsons; Aeron C Hurt; Miles P Davenport; Tom Kotsimbos; Allen C Cheng; Katherine Kedzierska; Xiaoyan Zhang; Jianqing Xu; Stephen J Kent Journal: JCI Insight Date: 2017-07-06
Authors: Jens Wrammert; Dimitrios Koutsonanos; Gui-Mei Li; Srilatha Edupuganti; Jianhua Sui; Michael Morrissey; Megan McCausland; Ioanna Skountzou; Mady Hornig; W Ian Lipkin; Aneesh Mehta; Behzad Razavi; Carlos Del Rio; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Zahida Ali; Kaval Kaur; Sarah Andrews; Rama Rao Amara; Youliang Wang; Suman Ranjan Das; Christopher David O'Donnell; Jon W Yewdell; Kanta Subbarao; Wayne A Marasco; Mark J Mulligan; Richard Compans; Rafi Ahmed; Patrick C Wilson Journal: J Exp Med Date: 2011-01-10 Impact factor: 14.307
Authors: Hillary A Vanderven; Fernanda Ana-Sosa-Batiz; Sinthujan Jegaskanda; Steven Rockman; Karen Laurie; Ian Barr; Weisan Chen; Bruce Wines; P Mark Hogarth; Teresa Lambe; Sarah C Gilbert; Matthew S Parsons; Stephen J Kent Journal: EBioMedicine Date: 2016-04-28 Impact factor: 8.143
Authors: Sai Priya Anand; Jérémie Prévost; Sophie Baril; Jonathan Richard; Halima Medjahed; Jean-Philippe Chapleau; William D Tolbert; Sharon Kirk; Amos B Smith; Bruce D Wines; Stephen J Kent; P Mark Hogarth; Matthew S Parsons; Marzena Pazgier; Andrés Finzi Journal: J Virol Date: 2019-01-17 Impact factor: 5.103
Authors: Patricia A Blundell; Dongli Lu; Mark Wilkinson; Anne Dell; Stuart Haslam; Richard J Pleass Journal: J Immunol Date: 2019-01-25 Impact factor: 5.422